2. Immunology/Inflammation Autophagy Anti-infection
  3. Toll-like Receptor (TLR) Autophagy SARS-CoV HSV
  4. Imiquimod dihydrochloride

Imiquimod dihydrochloride  (Synonyms: R 837 dihydrochloride)

Cat. No.: HY-B0180C
Handling Instructions Technical Support

Imiquimod (R 837) dihydrochloride, an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.

For research use only. We do not sell to patients.

CAS No. : 2995277-02-4

Size Price Stock Quantity
1 mg Get quote 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks
5 mg Get quote 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks
10 mg Get quote 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks
25 mg Get quote 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks
50 mg   Get quote  
100 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 48 publication(s) in Google Scholar

Other Forms of Imiquimod dihydrochloride:

Imiquimod dihydrochloride Related Antibodies

Top Publications Citing Use of Products

48 Publications Citing Use of MCE Imiquimod dihydrochloride

Histological Imaging/Staining
Bio/Physico-chemical Assay
RT-PCR
WB

    Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Apr 9;13(7):2226-2240.  [Abstract]

    Representative images of lung of mice after indicated treatment. PFI: ICG-loaded PF127 hydrogel, PFIR: ropivacaine-loaded PFI hydrogel, PFIM: imiquimod-loaded PFI hydrogel, PFIRM: imiquimod (3 mg) and ropivacaine co-loaded PFI hydrogel.

    Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Apr 9;13(7):2226-2240.  [Abstract]

    1. Cumulative release profile of ICG and Imiquimod (3 mg) from PFIRM with or without laser irradiation at 1.2 W/cm2 for 5 min. The absorbance of IMQ and ICG were measured at 320 and 800 nm, respectively, using a Micro UV-Vis Spectrophotometer (LIFEREAL, FC-1100). The assay was repeated three times.

    Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 May 14;20(1):228.  [Abstract]

    TEM image and magnified TEM Image of Zr-TCPP(TPP)/R837@M nanoparticles, scale bar: 200 nm.

    Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 May 14;20(1):228.  [Abstract]

    XPS spectra of Zr-TCPP(TPP)/R837@M.

    Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2022 Mar 4;3(1):e120.

    H&E staining of back skin sections of sham‐ or IMQ‐treated SHP2N KO and WT mice, scale bar = 200 μm.

    Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2022 Mar 4;3(1):e120.

    IMQ (10 μM, 2 h) treatment significantly increased the proportion of neutrophils in immune cells, while SHP099 treatment significantly decreased it.

    Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2022 Mar 4;3(1):e120.

    Results showed that neutrophil infiltration occurred in the skin tissues after IMQ (10 μM, 2 h) treatment, and SHP099 significantly reversed this phenomenon.

    Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: Cell Rep. 2021 Feb 2;34(5):108724.  [Abstract]

    Primary intestinal NFs were exposed to TLR agonists and IL-1 for 12 h, and OPN mRNA was measured using qPCR analysis. The results were normalized to β-actin. ∗p < 0.05. TLR agonists were used at the following concentrations: TLR1/2 agonist (Pam3CSK4), 100 ng/mL; TLR4 agonist (LPS), 1 μg/mL; TLR7 agonist (Imiquimod; HY-B0180), 100 ng/mL; TLR8 agonist (Motolimod; HY-13773), 250 ng/mL; and IL-1, 5 ng/ml.

    Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2016 May 25;7:11724.  [Abstract]

    Freshly prepared splenic B cells are left unstimulated (lanes 1 and 4), or stimulated by 10 μg/mL αIgM for 6 or 24 h (lanes 2 and 3), or by 1 μg/mL IMQ for 6, 24, 48 and 72 h (lanes 5-8), or by αIgM and IMQ for 24 or 48 h (lanes 9+10), respectively.

    View All Toll-like Receptor (TLR) Isoform Specific Products:

    View All Isoforms
    TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

    View All HSV Isoform Specific Products:

    View All Isoforms
    HSV-1 HSV-2 HSV

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Imiquimod (R 837) dihydrochloride, an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

    In Vivo

    Imiquimod (IMQ) can be used to induce psoriasis models[5].

    Induction of psoriasis Model[5]
    Background
    Lmiquimod (IMQ) induces inflamed scaly skin lesions resembling plaque-type psoriasis. IMQ induces epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells.
    Specific Mmodeling Methods
    Mice: BALB/c • male • 8-week-old
    Administration: 3.125 mg/day • skin • 6 days
    Note
    IMQ cream preparation [7]:
    (1) Prepare BM of lipids
    STA and OA were melted at 75 °C followed by the addition of IMQ (3.5% of the BM, w/w) under continuous stirring.
    Polysorbate 80 and stearoyl polyoxyl-32 glycerides at a 50:50 ratio were dispersed in water heated separately to 75 °C and added to the BM phase under continuous stirring.
    (2) Prepare nanostructured lipid carriers (NLCs)
    The mixture was then subjected to high-shear homogenization followed by ultrasonication.
    The mixture was then rapidly cooled in an ice bath to allow the formation of NLCs.
    Modeling Indicators
    Behavior Observation: Induced the back skin of the mice started to display signs of erythema, scaling, and thickening.
    Resulted in hyperproliferative keratinocytes and a disturbed epidermal differentiation (parakeratosis).

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    313.23

    Formula

    C14H18Cl2N4
    CAS No.
    SMILES

    NC1=NC2=C(C3=C1N=CN3CC(C)C)C=CC=C2.Cl.Cl
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Imiquimod dihydrochloride Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Imiquimod2995277-02-4R 837R837R-837Toll-like Receptor (TLR)AutophagySARS-CoVHSVSARS coronavirusHerpes simplex virushumanpapillomaviruswartsmolluscumcontagiosumactinickeratosisbasal ,cellcarcinomasquamouscellBowen'sdiseasenongenitalinfectionvulvarintraepithelialneoplasiaInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Imiquimod dihydrochloride
    Cat. No.:
    HY-B0180C
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.